We advised Forbion European Acquisition, a SPAC, on its IPO and Nasdaq listing

Davis Polk advised Forbion European Acquisition Corp. on its $126.5 million initial public offering of 12,650,000 units, including 1,650,000 units sold pursuant to the full exercise of the underwriters’ over-allotment option. Each unit had an initial offering price of $10 and consists of one Class A ordinary share and one-third of one redeemable warrant. The units, the shares and the warrants are listed on the Nasdaq Global Market.

Forbion European Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated for the purpose of effecting a business combination with one or more businesses or entities. Forbion European Acquisition Corp. has not yet selected any specific business combination target, and intends to focus on the life sciences industry.

The Davis Polk corporate team included partners Leo Borchardt and Derek Dostal and associates Maxim Van de moortel, Serdar Inci, Sana Bargach and Saratu M. Kitchener. The tax team included counsel Alon Gurfinkel and associate Ben Levenback. Members of the Davis Polk team are based in the London and New York offices.